Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2017 (2017), Article ID 5074891, 4 pages
https://doi.org/10.1155/2017/5074891
Case Report

Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring

1Internal Medicine, Easton Hospital, Easton, PA, USA
2Drexel University College of Medicine, Philadelphia, PA, USA
3Easton Hospital, PA, USA

Correspondence should be addressed to Munish Sharma

Received 4 December 2016; Accepted 10 January 2017; Published 26 January 2017

Academic Editor: Antonio de Padua Mansur

Copyright © 2017 Munish Sharma and Daniel A. N. Mascarenhas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. L. Anderson, C. D. Adams, E. M. Antman et al., “ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with,” Circulation, vol. 116, no. 7, pp. e148–e304, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Andell, S. K. James, C. P. Cannon et al., “Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial,” Journal of the American Heart Association, vol. 4, no. 10, Article ID e002490, 2015. View at Publisher · View at Google Scholar
  3. R. F. Storey, S. Husted, R. A. Harrington et al., “Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes,” Journal of the American College of Cardiology, vol. 50, no. 19, pp. 1852–1856, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Wallentin, R. C. Becker, A. Budaj et al., “Ticagrelor versus clopidogrel in patients with acute coronary syndromes,” The New England Journal of Medicine, vol. 361, pp. 1045–1057, 2009. View at Google Scholar
  5. R. D. Turgeon, K. A. Fernandes, D. Juurlink, J. V. Tu, and M. Mamdani, “Ticagrelor and bradycardia: a nested case—control study,” Pharmacoepidemiology and Drug Safety, vol. 24, no. 12, pp. 1281–1285, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Goldberg, I. Rosenfeld, I. Nordkin, and M. Halabi, “Life-threatening complete atrioventricular block associated with ticagrelor therapy,” International Journal of Cardiology, vol. 182, pp. 379–380, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Bonello, M. Laine, N. Kipson et al., “Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome,” Journal of the American College of Cardiology, vol. 63, no. 9, pp. 872–877, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Ünlü, S. Demirkol, A. O. Yildirim, Ş. Balta, C. Öztürk, and A. Iyisoy, “Atrioventricular block associated with ticagrelor therapy may require permanent pacemaker,” International Journal of Cardiology, vol. 202, pp. 946–947, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Ozturk, M. Unlu, A. O. Yildirim et al., “The progressed atrioventricular block associated with ticagrelor therapy may not require permanent pacemaker after acute coronary syndrome; it may be reversible,” International Journal of Cardiology, vol. 203, pp. 822–824, 2016. View at Publisher · View at Google Scholar · View at Scopus